Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

The mitogen-activated protein kinases (MAPK) pathway, often known as the RAS-RAF-MEK-
ERK signal cascade, functions to transmit upstream signals to its downstream effectors to …

Abstract Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in
BRAF-and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 …

Abstract The RAS–RAF–MEK–ERK signalling pathway is hyperactivated in a high
percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and
other diseases. Currently, more than 25 oncology drugs that target kinases have been …

The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale
for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and …

Aberrant activation of signaling through the RAS–RAF–MEK–ERK (MAPK) pathway is
implicated in numerous cancers, making it an attractive therapeutic target. Although BRAF …

Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …